Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction

Leukemia and Lymphoma

Volumn 46, Issue 11, 2005, Pages 1667-1670

  Onitilo, Adedayo A ^a   Kio, Ebenezer A ^b   Singh, Avtar K ^d   Lazarchick, John ^c  

^a MARSHFIELD CLINIC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Cytogenetics; FIP1 like 1 platelet derived growth factor alpha (FIP1L1 PDGFRA); Hypereosinophilic syndrome; Imatinib; Remission; Tyrosine kinase

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; IMATINIB;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYTOGENETICS; CYTOPENIA; FATIGUE; HEART DISEASE; HEART HYPERTROPHY; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; HYPEREOSINOPHILIC SYNDROME; LOW DRUG DOSE; MALE; MITRAL VALVE REGURGITATION; PERICARDIAL EFFUSION; PRIORITY JOURNAL; REMISSION; TRICUSPID VALVE REGURGITATION; TRISOMY 8;

AORTIC VALVE INSUFFICIENCY; CARDIOMEGALY; CHROMOSOMES, HUMAN, PAIR 8; CYTOGENETIC ANALYSIS; HEART DISEASES; HUMANS; HYPEREOSINOPHILIC SYNDROME; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; TRISOMY;

EID: 28244496082     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500220514     Document Type: Article

References (21)

1. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 2004;11:51-57.
2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214.
3. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of 14 cases with review of the literature. Medicine (Baltimore) 1975;54:1-27.
4. Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In: Jaffe E, Harris N, Stein H, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, International Agency for Research on Cancer; 2001. pp 29-34.
5. Apperley J, Bain B. The FIP1L1-PDGFRA syndrome: a case of mistaken identity? Blood 2004;104:2999-3000.
6. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104:3038-3045.
7. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
8. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113-122.
9. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103: 2873-2878.
10. Druker BJ. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. J Clin Oncol 2003; 21(Suppl 3): 239S-245S.
11. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004;103:2879-2891.
12. Wolf D, Gastl G, Rumpold H. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib]. Dtsch Med Wochenschr 2004;129:2104-2106.
13. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 2001;3:9.
14. Fujii N, Ikeda K, Takahashi N, Kojima K, Kobayashi Y, Ashiba A, et al. Multilineage involvement in hypereosinophilic syndrome terminating in granulocytic sarcoma and leukaemic transformation with trisomy 8. Br J Haematol 2002;119: 716-719.
15. Guitard AM, Horschowski N, Mozziconacci MJ, Michel G, George F, Capodano AM, et al. Hypereosinophilic syndrome in childhood: trisomy 8 and transformation to mixed acute leukaemia. Nouv Rev Fr Hematol 1994;35:555-559.
16. Kobayashi M, Katayama T, Ochiai S, Yoshida M, Kaito K, Masuoka H, et al. [Interferon-alpha therapy in the myeloproliferative variants of hypereosinophilic syndrome]. Rinsho Ketsueki 1993;34:367-372.
17. Lynott A, Ravandi-Kashani F, Giles FJ. Malignancy: case report: hypereosinophilia progressing to granulocytic sarcoma and acute myelocytic leukemia with trisomy 8: a case report and review of the literature. Hematology 2000; 4:487-493.
18. Quiquandon I, Claisse JF, Capiod JC, Delobel J, Prin L. alpha-Interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission. Blood 1995;85:2284-2285.
19. Salem Z, Zalloua PA, Chehal A, Bitar N, Abboud M, Kadri A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J 2003;4:410-412.
20. Anghel G, De Rosa L, Ruscio C, Petti N, Riccardi M, Severino A, et al. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement. Tumori 2005;91:67-70.
21. Lefebvre C, Bletry O, Degoulet P, Guillevin L, Bentata-Pessayre M, Le Thi Huong D, et al. [Prognostic factors of hypereosinophilic syndrome. Study of 40 cases]. Ann Med Interne (Paris) 1989;140:253-257.